219 related articles for article (PubMed ID: 36947281)
21. Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis.
Song Y; Li X; He X; Zhou F; Du F; Wang Z; Chen S; Wu D
Front Immunol; 2023; 14():1211655. PubMed ID: 37457729
[TBL] [Abstract][Full Text] [Related]
22. Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: A cautionary tale.
Trantham T; Auten J; Muluneh B; Van Deventer H
J Oncol Pharm Pract; 2020 Jun; 26(4):1005-1008. PubMed ID: 31575356
[TBL] [Abstract][Full Text] [Related]
23. An analysis of reported cases of hemophagocytic lymphohistiocytosis (HLH) after COVID-19 vaccination.
Zhang HQ; Cao BZ; Cao QT; Hun M; Cao L; Zhao MY
Hum Vaccin Immunother; 2023 Aug; 19(2):2263229. PubMed ID: 37811764
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of hemophagocytic lymphohistiocytosis in a patient with systemic lupus erythematosus with ruxolitinib: a case report.
Jung JI; Kim JY; Kim MH; Park JK; Lee EY; Lee EB; Park JW
J Rheum Dis; 2024 Apr; 31(2):125-129. PubMed ID: 38559795
[TBL] [Abstract][Full Text] [Related]
25. Adult macrophage activation syndrome-haemophagocytic lymphohistiocytosis: 'of plasma exchange and immunosuppressive escalation strategies' - a single centre reflection.
Lorenz G; Schul L; Schraml F; Riedhammer KM; Einwächter H; Verbeek M; Slotta-Huspenina J; Schmaderer C; Küchle C; Heemann U; Moog P
Lupus; 2020 Mar; 29(3):324-333. PubMed ID: 32013725
[TBL] [Abstract][Full Text] [Related]
26. Diagnosing and treating hemophagocytic lymphohistiocytosis in the tropics: systematic review from the Indian subcontinent.
Rajagopala S; Singh N
Acta Med Acad; 2012; 41(2):161-74. PubMed ID: 23331391
[TBL] [Abstract][Full Text] [Related]
27. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
[TBL] [Abstract][Full Text] [Related]
28. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
[TBL] [Abstract][Full Text] [Related]
29. Case report: Optimized ruxolitinib-based therapy in an infant with familial hemophagocytic lymphohistiocytosis type 3.
Niizato D; Isoda T; Mitsuiki N; Kaneko S; Tomomasa D; Kamiya T; Takagi M; Imai K; Kajiwara M; Shimizu M; Morio T; Kanegane H
Front Immunol; 2022; 13():977463. PubMed ID: 36505485
[TBL] [Abstract][Full Text] [Related]
30. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis.
Henzan T; Nagafuji K; Tsukamoto H; Miyamoto T; Gondo H; Imashuku S; Harada M
Am J Hematol; 2006 Jan; 81(1):59-61. PubMed ID: 16369976
[TBL] [Abstract][Full Text] [Related]
31. Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis.
Chi Y; Liu R; Zhou ZX; Shi XD; Ding YC; Li JG
Pediatr Rheumatol Online J; 2021 Apr; 19(1):49. PubMed ID: 33794928
[TBL] [Abstract][Full Text] [Related]
32. Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience.
Marsh RA; Jordan MB; Talano JA; Nichols KE; Kumar A; Naqvi A; Vaiselbuh SR;
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27786410
[TBL] [Abstract][Full Text] [Related]
33. A Case of Hemophagocytic Lymphohistiocytosis following Second Dose of COVID-19 Vaccination.
Park HW; Min GJ; Kim TY; Cho SG
Acta Haematol; 2023; 146(1):65-71. PubMed ID: 36096118
[TBL] [Abstract][Full Text] [Related]
34. Treatment of hemophagocytic lymphohistiocytosis with alemtuzumab in systemic lupus erythematosus.
Keith MP; Pitchford C; Bernstein WB
J Clin Rheumatol; 2012 Apr; 18(3):134-7. PubMed ID: 22426581
[TBL] [Abstract][Full Text] [Related]
35. Hemophagocytic Lymphohistiocytosis in the Elderly.
Altook R; Ruzieh M; Singh A; Alamoudi W; Moussa Z; Alim H; Safi F; Duggan J
Am J Med Sci; 2019 Jan; 357(1):67-74. PubMed ID: 30278875
[TBL] [Abstract][Full Text] [Related]
36. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.
Ahmed A; Merrill SA; Alsawah F; Bockenstedt P; Campagnaro E; Devata S; Gitlin SD; Kaminski M; Cusick A; Phillips T; Sood S; Talpaz M; Quiery A; Boonstra PS; Wilcox RA
Lancet Haematol; 2019 Dec; 6(12):e630-e637. PubMed ID: 31537486
[TBL] [Abstract][Full Text] [Related]
37. JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition.
Chaturvedi V; Lakes N; Tran M; Castillo N; Jordan MB
Blood; 2021 Sep; 138(12):1034-1039. PubMed ID: 34232994
[TBL] [Abstract][Full Text] [Related]
38. Ruxolitinib as first-line therapy in secondary hemophagocytic lymphohistiocytosis and HIV infection.
Gálvez Acosta S; Javalera Rincón M
Int J Hematol; 2020 Sep; 112(3):418-421. PubMed ID: 32285358
[TBL] [Abstract][Full Text] [Related]
39. Pregnancy-Induced Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review.
Zhao J; Yang YM; Ming SH
Chin Med Sci J; 2020 Dec; 35(4):371-376. PubMed ID: 33413754
[TBL] [Abstract][Full Text] [Related]
40. Combined IFN-γ and JAK inhibition to treat hemophagocytic lymphohistiocytosis in mice.
Joly JA; Vallée A; Bourdin B; Bourbonnais S; Patey N; Gaboury L; Théorêt Y; Decaluwe H
J Allergy Clin Immunol; 2023 Jan; 151(1):247-259.e7. PubMed ID: 35973477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
